[Prader-Willi syndrome: metabolic aspects related to growth hormone treatment].
OBJECTIVE
The focus of this study was to evaluate the metabolic profile of Prader-Willi Syndrome (PWS) patients treated with growth hormone.


METHODS
Seven patients (four boys and three girls) with ages between six years and six months and 14 years and 11 months were treated with GH 0.1 U/kg/day subcutaneous by six times a week, for two years. Anthropometric data, lipids, glucose, IGF-I and body composition were evaluated at baseline and after 12 and 24 months.


RESULTS
IGF-I levels increased in all cases. Skin folds decreased. The mean reduction in body fat was 5.0% and the mean increased in lean mass was 7.6 kg in the prepubertal patients. The pubescent girl increased 4.8 kg and showed a 5.6% decrease in fat mass. A mean gain in the bone mass was 0.07 g/cm(2) (7.3%) in prepubescent cases, and 0.02 g/cm(2) (2.0%) in the pubescent girl.


CONCLUSIONS
In our study GH treatment improved lean body and bone masses and had beneficial effect on lipid values.
Kuo
Jack Y
JY
Unidade de Endocrinologia Pediátrica, Instituto da Criança, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo. jackyk@ig.com.br
Ditchekenian
Vaê
V
Manna
Thaís D
TD
Kuperman
Hilton
H
Damiani
Durval
D
Setian
Nuvarte
N
D017667:Adipocytes / Q000378:metabolism; D000273:Adipose Tissue / Q000378:metabolism; D000293:Adolescent; D001823:Body Composition / Q000187:drug effects* / Q000502:physiology; D015992:Body Mass Index; D002648:Child; D005260:Female; D019382:Human Growth Hormone / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D050356:Lipid Metabolism / Q000187:drug effects*; D008297:Male; D011218:Prader-Willi Syndrome / Q000188:drug therapy / Q000378:metabolism*; D012885:Skinfold Thickness; D015430:Weight Gain / Q000187:drug effects
D019382:Human Growth Hormone; D007334:Insulin-Like Growth Factor I